• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:AU2006255183A1
    申请号:U2006255183
    申请日:2006-06-02
    公开日:2006-12-14
    发明作者:Sanjay Mistry
    申请人:Centocor Inc；
    IPC主号:A61K48-00
    专利说明:
    WO 2006/133052 PCT/US2006/021671 A CELLULAR THERAPY FOR OCULAR DEGENERATION FIELD OF THE INVENTION This invention relates to the field of cell-based or regenerative therapy for ophthalmic diseases and disorders. In particular, the invention provides mesenchymal stem cells, and 5 methods, optionally with pharmaceutical compositions, devices for the regeneration or repair of cells and tissues of the eye. BACKGROUND As a complex and sensitive organ of the body, the eye can experience numerous diseases and other deleterious conditions that affect its ability to function normally. Many of 10 these conditions are associated with damage or degeneration of specific ocular cells, and tissues made up of those cells. As one example, diseases and degenerative conditions of the optic nerve and retina are the leading causes of blindness throughout the world. Damage or degeneration of the cornea, lens and associated ocular tissues represent another significant cause of vision loss. The retina contains seven layers of alternating 15 cells and processes that convert a light signal into a neural signal. The retinal photoreceptors and adjacent retinal pigment epithelium (RPE) form a functional unit that, in many disorders, becomes unbalanced due to genetic mutations or environmental conditions (including age). This results in loss of photoreceptors: through apoptosis or secondary degeneration, which leads to progressive deterioration of vision and, in some 20 instances, to blindness (for a review, see, e.g., Lund, R.D. et al., 2001, Progress in Retinal and Eye Research 20: 415-449). Two classes of ocular disorders that fall into this pattern are age-related macular degeneration (AMD) and retinitis pigmentosa (RP). AMD is the most common cause of vision loss in the United States in those 50 or older; and its prevalence increases with age. The primary disorder in AMD appears to be due to 25 RPE dysfunction and changes in Bruch's membranes, e.g., lipid deposition, protein cross linking and decreased permeability to nutrients (Lund et al., 2001). A variety of elements may contribute to macular degeneration, including genetic makeup, age, nutrition, smoking and exposure to sunlight.
    WO 2006/133052 PCT/US2006/021671 RP is mainly considered an inherited disease: over 100 mutations have been associated with photoreceptor loss (Lund et al., 2001). Though the majority of mutations target photoreceptors, some affect RPE cells directly. Together, these mutations affect such processes as molecular trafficking between photoreceptors and RPE cells and 5 phototransduction, for example. Other less common, but nonetheless debilitating retinopathies can also involve progressive cellular degeneration leading to vision loss and blindness. These include, for example, diabetic retinopathy and choroidal neovascular membrane (CNVM). Diabetic retinopathy may be classified as (1) non-proliferative or background retinopathy, 10 characterized by increased capillary permeability, edema, hemorrhage, microaneurysms, and exudates, or 2) proliferative retinopathy, characterized by neovascularization extending from the retina to the vitreous, scarring, fibrous tissue formation, and potential for retinal detachment. In CNVM, abnormal blood vessels stemming from the choroid grow up through the retinal layers. The fragile new vessels break easily, causing blood 15 and fluid to pool within the layers of the retina. Damage or progressive degeneration of the optic nerve and related nerves of the eye constitutes another leading cause of vision loss and blindness. A prime example is glaucoma, a condition of the eye that is made up of a collection of eye diseases that cause vision loss by damage to the optic nerve. Elevated intraocular pressure (IOP) due to 20 inadequate ocular drainage is a primary cause of glaucoma, but it can also develop in the absence of elevated IOP. Glaucoma can develop as the eye ages, or it can occur as the result of an eye injury, inflammation, tumor, or in advanced cases of cataract or diabetes, or it can be caused by certain drugs, such as, for example steroids. The primary features of the optic neuropathy 25 in glaucoma include characteristic changes in the optic nerve head, a decrease in number of surviving retinal ganglion cells, and loss of vision. It has been proposed that a cascade of events links degeneration of the optic nerve head with the slow death of retinal ganglion cells observed in the disease, and that this cascade of events can be slowed or 2 WO 2006/133052 PCT/US2006/021671 prevented through the use of neuroprotective agents (Osborne et al., 2003, Eur. J. Ophthalmol, 13 (Supp 3): S19-S26). Cellular damage and degenerative conditions also affect other parts of the eye. For example, cataracts result from gradual opacification of the crystalline lens of the eye. It 5 is believed that once begun, cataract development proceeds along one or more common pathways that culminate in damage to lens fibers. This condition is presently treated by surgical removal and replacement of the affected lens. Another example concerns the cornea and surrounding conjuctiva that make up the ocular surface. The limbal epithelium, located between the cornea and the bulbar conjuctiva, contains corneal 10 epithelial stem cells. Limbal epithelial cell deficiency (LECD) is a condition that occurs, for example, in Stevens-Johnson syndrome and thermal or chemical burns. LECD often leads to an imbalance between the corneal epithelium and the conjunctival epithelium in which the cornea is covered by invading conjunctival epithelial cells, which severely compromises the corneal surface and affects visual acuity (Nakamura, T. &Kinoshita, S., 15 2003. Cornea 22 (Supp. 1): S75-S80). The recent advent of stem cell-based therapy for tissue repair and regeneration provides promising treatments for a number of aforementioned cell-degenerative pathologies and other ocular disorders. Stem cells are capable of self-renewal and differentiation to generate a variety of mature cell lineages. Transplantation of such cells can be utilized as 20 a clinical tool for reconstituting a target tissue, thereby restoring physiologic and anatomic functionality. The application of stem cell technology is wide-ranging, including tissue engineering, gene therapy delivery, and cell therapeutics, i.e., delivery of bio-therapeutic agents to a target location via exogenously supplied living cells or cellular components that produce or contain those agents (For a review, see Tresco, P.A. et al., 25 2000, Advanced Drug Delivery Reviews 42: 2-37). An obstacle to realization of the therapeutic potential of stem cell technology has been difficulty in obtaining sufficient numbers of stem cells. One source of stem cells is embryonic or fetal tissue. Embryonic stem and progenitor cells have been isolated from a number of mammalian species, including humans, and several such cell types have been 3 WO 2006/133052 PCT/US2006/021671 shown capable of self-renewal and expansion, as well differentiation into a variety of cell lineages. In animal model systems, embryonic stem cells have been reported to differentiate into a RPE cell phenotype, as well as to enhance the survival of host photoreceptors following transplantation (Haruta, M. et al., 2004, Investig. Ophthalmol. 5 Visual Sci. 45: 1020-1025; Schraermeyer, U. et al., 2001, Cell Transplantation 10: 673 680). But the derivation of stem cells from embryonic or fetal sources has raised many ethical issues that are desirable to avoid by identifying other sources of multipotent or pluripotent cells. Adult tissue also can yield stem cells useful for cell-based ocular therapy. For instance, 10 retinal and corneal stem cells themselves may be utilized for cell replacement therapy in the eye. In addition, neural stem cells from the hippocampus have been reported to integrate with the host retina, adopting certain neural and glial characteristics (see review of Lund, R.L. et al., 2003, J. Leukocyte Biol. 74: 151-160). Neural stem cells prepared from fetal rat cortex were shown to differentiate along an RPE cell pathway following 15 transplantation into the adult rat subretinal space (Enzmann, V. et al., 2003, Investig. Ophthalmol. Visual Sci. : 5417-5422). Bone marrow stem cells have been reported to differentiate into retinal neural cells and photoreceptors following transplantation into host retinas (Tomita, M. et al., 2002, Stem Cells 20: 279-283; Kicic, A. et al., 2003, J. Neurosci. 23: 7742-7749). Kicic, A. et al. 20 reports that CD90 mesenchymal stem cells were capable of integrating into the host retina. These cells underwent differentiation, forming structures similar to the photoreceptor layer and expressed a photoreceptor-specific marker. Friedlander et al (published U.S. Patent Application US2005/0063961, assigned to The Scripps Research Institute, CA) report the rescue of blood vessels and neuronal networks 25 in the eye by the injection of Lin7CD31* hematopoetic stem cells into the eye. An ocular surface reconstruction in a rabbit model system, utilizing cultured mucosal epithelial stem cells, has also been reported (Nakamura, T. & Kinoshita, S., 2003, supra). While these reports show promise for the use of adult progenitor and stem cells in cell 4 WO 2006/133052 PCT/US2006/021671 based therapy for the eye, it must be noted that adult stem cell populations are comparatively rare and are often obtainable only by invasive procedures. Further, adult stem cells may have a more limited ability to expand in culture than do embryonic stem cells. Thus, a need exists for alternative sources of adequate supplies of 5 cells having the ability to support, augment or replace lost cellular function in the eye. A reliable, well-characterized and plentiful supply of substantially homogeneous populations of such cells would be an advantage in a variety of diagnostic and therapeutic applications in ocular repair and regeneration, including drug screening assays, ex vivo or in vitro trophic support of ocular and other useful cell types, and in vivo cell- based 10 therapy. To this end, the present invention is directed toward the use of cell lines as a therapy for ocular disease. Several cell lines were tested in a rodent model of retinitis pigmentosa, according to methods disclosed in published U.S. Patent Application US2005/0037491. The present invention describes the use of human mesenchymal stem cells as being 15 useful as a therapy for ocular disease. SUMMARY This invention provides compositions and methods applicable to cell-based or regenerative therapy for ophthalmic diseases and disorders. In particular, the invention features mesenchymal stem cells, optionally with pharmaceutical compositions or devices 20 for the repair or regeneration of cells or tissues of the eye. Once transplanted into a target location in the eye, the mesenchymal stem cells of the invention may provide trophic support for ocular cells in situ, or they may themselves differentiate into one or more phenotypes, or they may exert a beneficial effect in both of those fashions, but the cells do not form structures similar to the photoreceptor layer and do not express a 25 photoreceptor-specific marker, such as rhodopsin. One aspect of the invention features a method of treating a patient having an ocular degenerative condition, which comprises administering to the patient multipotent or pluripotent mesenchymal stem cells, in an amount effective to treat the ocular 5 WO 2006/133052 PCT/US2006/021671 degenerative condition. In certain embodiments, the ocular degenerative condition is an acute ocular degenerative condition such as brain trauma, optic nerve trauma or ocular lesion. In other embodiments, it is a chronic or progressive degenerative condition, such as macular degeneration, retinitis pigmentosa, diabetic retinopathy, glaucoma, a limbal 5 epithelial cell deficiency, or a retinal pigment epithelial cell deficiency. In certain embodiments, the cells are induced in vitro to differentiate into a neural or epithelial lineage cells prior to administration. In one embodiment, the mesenchymal stem cells promote the survival or proliferation of endogenous photoreceptors in the eye. In an alternate embodiment, the mesenchymal 10 stem cells promote the differentiation of endogenous stem cells or precursor cells to photoreceptors. In one embodiment, the mesenchymal stem cells are positive for the expression of at least one of the following markers: CD29, CD44, CD105 or CD166. The cells are negative for the expression of at least one of the following markers: CD14, CD34 or CD45. 15 In certain embodiments, the cells may be administered with at least one other cell type, such as, for example, an astrocyte, an oligodendrocyte, a neuron, a neural progenitor cell, a neural stem cell, a retinal epithelial stem cell, a corneal epithelial stem cell, or an other multipotent or pluripotent stem cell. In these embodiments, the other cell type may be administered simultaneously with, or before, or after, the mesenchymal stem cells. 20 Likewise, in these and other embodiments, the cells may be administered with at least one other agent, such as a drug for ocular therapy, or another beneficial pharmaceutical agent such as, for example, an anti-inflammatory agent, an anti-apoptotic agent, an antioxidant or a growth factor. In these embodiments, the other agent may be administered simultaneously with, before, or after, the mesenchymal stem cells. 25 The mesenchymal stem cell suitable for use in the present invention may be derived from tissues such as, for example, bone marrow, umbilical cord blood, amniotic sac and fluid, placenta, skin, fat, muscle, vasculature, liver, pancreas, or peripheral blood. The cells may be xenogeneic, allogeneic or autologous in origin. The cells may be isolated from 6 WO 2006/133052 PCT/US2006/021671 the donor and transplanted immediately. Alternatively, the cells may be expanded in vitro prior to transplantation. The cells of the present invention may be cryogenically stored. Prior to transplantation, the cells may be thawed and transplanted immediately. Alternatively, the thawed cells 5 may be cultured and/or expanded in vitro prior to transplantation. Alternatively, the cells may be transplanted as a frozen pellet. In various embodiments, the cells may be administered to the surface of an eye, or they may be administered to the interior of an eye or to a location in proximity to the eye, such as, for example, behind the eye, or the sub-retinal space. 10 The cells may be administered through a cannula or from a device implanted in the patient's body within or in proximity to the eye, or they may be administered by implantation of a matrix or support containing the cells. Another aspect of the invention features a pharmaceutical composition for treating a patient having an ocular degenerative condition, comprising a pharmaceutically 15 acceptable carrier and the mesenchymal stem cells of the present invention in an amount effective to treat the ocular degenerative condition. The ocular degenerative condition may be an acute, chronic or progressive condition. In certain embodiments, the composition comprises the mesenchymal cells of the present invention that have been induced in vitro to differentiate into a neural or epithelial lineage cells prior to 20 formulation of the composition. Alternatively, the composition comprises the mesenchymal stem cells of the present invention that differentiate into a neural or epithelial lineage cells in situ, post transplantation. In certain embodiments, the pharmaceutical composition may comprise at least one other cell type, such as an astrocyte, an oligodendrocyte, a neuron, a neural progenitor cell, a 25 neural stem cell, a retinal epithelial stem cell, a corneal epithelial stem cell, or an other multipotent or pluripotent stem cell. In these or other embodiments, the pharmaceutical composition may comprise at least one other agent, such as a drug for treating the ocular 7 WO 2006/133052 PCT/US2006/021671 degenerative disorder or other beneficial pharmaceutical agents, such as, for example, anti-inflammatory agents, anti-apoptotic agents, antioxidants or growth factors. In certain embodiments, the pharmaceutical compositions may be formulated for administration to the surface of an eye. Alternatively, they may be formulated for 5 administration to the interior of an eye or in proximity to the eye (e.g., behind the eye). The compositions may also be formulated as a matrix or support containing the cells. According to yet another aspect of the invention, a kit is provided for treating a patient having an ocular degenerative condition. The kit may comprise a pharmaceutically acceptable carrier, a population of mesenchymal stem cells, and instructions for using the 10 kit in a method of treating the patient. The kit may also contain one or more additional components, such as reagents and instructions for culturing the cells, or a population of at least one other cell type, or one or more agents useful in the treatment of an ocular degenerative condition. Another aspect of the invention features a method for increasing the survival, growth or 15 activity of cells for transplantation to treat an ocular degenerative disorder. The method comprises contacting mesenchymal stem cells with at least one pharmaceutical agent, such as, for example, growth factors, trophic factors, conditioned medium, anti inflammatory agents, anti apoptotic agents, antioxidants, neurotrophic factors or neuroregenerative or neuroprotective drugs. Alternatively, the method may comprise co 20 culturing mesenchymal stem cells with at least one other cell type, such as an astrocyte, an oligodendrocyte, a neuron, a neural progenitor cell, a neural stem cell, a retinal epithelial stem cell, a corneal epithelial stem cell, or other multipotent or pluripotent stem cell, prior to transplantation. Agents, such as, for example, growth factors, trophic factors, conditioned medium, anti-inflammatory agents, anti apoptotic agents, 25 antioxidants, neurotrophic factors or neuroregenerative or neuroprotective drugs may be added. A kit for practicing the method is also provided. The kit comprises mesenchymal stem cells and instructions for treating the cells with the at least one agent effective to increase the survival, growth or activity of the cells for transplantation. The kit may 8 WO 2006/133052 PCT/US2006/021671 include at least one other cell type and instructions on the co-culture of the at least one other cell type with mesenchymal stem cells. 9 WO 2006/133052 PCT/US2006/021671 BRIEF DESCRIPTION OF THE DRAWINGS Figure 1: Summary of ERG recordings from RCS rats receiving cellular transplants. Data shown is the mean amplitude of the ERG recordings (mV) obtained from rats at 60 (panel A) and 90 days (panel B) post transplantation (n=5 animals per 5 condition). Recordings were taken from the eyes of rats receiving umbilical-derived cells (black bars) and the contralateral sham operated eye (black hashed bars). Recordings were taken from the eyes of rats receiving Cambrex MSC's (POIETICSTM, Cat. No PT 2501) (gray bars) and the contralateral sham operated eye (gray hashed bars). Recordings were taken from the eyes of rats receiving placental-derived cells (white bars) and the 10 contralateral sham operated eye (gray horizontally striped bars). Figure 2: Visual acuity of RCS rats receiving MSC's of the present invention. Data shown is the visual acuity of animals at 4 months of age (n=7), from sham operated rats (white bars), or MSC's of the present invention (Black bars). Figure 3: Visual thresholds of RCS rats receiving MSC's of the present invention. 15 Data shown is the visual acuity of animals at 4 months of age (n=7) that received grafts of MSC's in the left (A) or right (*) eye. Data from contralateral sham operated eyes (left A: right U) were included as controls. Figure 4: A histological section of a retina from an animal receiving MSC's of the present invention. Tissue section was obtained from a grafted animal 100 days post 20 procedure. DETAILED DESCRIPTION The terms "ocular", "ophthalmic" and "optic" are used interchangeably herein to define "of, or about, or related to the eye." The term "ocular degenerative condition" (or "disorder") is an inclusive term encompassing acute and chronic conditions, disorders or 25 diseases of the eye, inclusive of the neural connection between the eye and the brain, involving cell damage, degeneration or loss. An ocular degenerative condition may be age- related, or it may result from injury or trauma, or it may be related to a specific 10 WO 2006/133052 PCT/US2006/021671 disease or disorder. Acute ocular degenerative conditions include, but are not limited to, conditions associated with cell death or compromise affecting the eye including conditions arising from cerebrovascular insufficiency, focal or diffuse brain trauma, diffuse brain damage, infection or inflammatory conditions of the eye, retinal tearing or 5 detachment, intra- ocular lesions (contusion penetration, compression, laceration) or other physical injury (e.g., physical or chemical burns). Chronic ocular degenerative conditions (including progressive conditions) include, but are not limited to, retinopathies and other retinal/macular disorders such as retinitis pigmentosa (RP), age-related macular degeneration (AMD), choroidal neovascular membrane (CNVM); retinopathies such as 10 diabetic retinopathy, occlusive retinopathy, sickle cell retinopathy and hypertensive retinopathy, central retinal vein occlusion, stenosis of the carotid artery, optic neuropathies such as glaucoma and related syndromes; disorders of the lens and outer eye, e. g., limbal stem cell deficiency (LSCD), also referred to as limbal epithelial cell deficiency (LECD), such as occurs in chemical or thermal injury, Steven-Johnson 15 syndrome, contact lens-induced keratopathy, ocular cicatricial pemphigoid, congenital diseases of aniridia I or ectodermal dysplasia, and multiple endocrine deficiency associated keratitis. The term treating (or treatment of) an ocular degenerative condition refers to ameliorating the effects of, or delaying, halting or reversing the progress of, or delaying or preventing the onset of, an ocular degenerative condition as defined herein. 20 The term "effective amount" refers to a concentration or amount of a reagent or pharmaceutical composition, such as a growth factor, differentiation agent, trophic factor, cell population or other agent, that is effective for producing an intended result, including cell growth and/or differentiation in vitro or in vivo, or treatment of ocular degenerative conditions, as described herein. With respect to growth factors, an effective amount may 25 range from about 1 nanogram/milliliter to about 1 microgram/milliliter. With respect to MSC's as administered to a patient in vivo, an effective amount may range from as few as several hundred or fewer to as many as several million or more. In specific embodiments, an effective amount may range from 103, more specifically at least about 104 cells. It will be appreciated that the number of cells to be administered will vary 30 depending on the specifics of the disorder to be treated, including but not limited to size 11 WO 2006/133052 PCT/US2006/021671 or total volume/surface area to be treated, as well as proximity of the site of administration to the location of the region to be treated, among other factors familiar to the medicinal biologist. The terms "effective period" (or "time") and "effective conditions" refer to a period of 5 time or other controllable conditions (e.g., temperature, humidity for in vitro methods), necessary or preferred for an agent or pharmaceutical composition to achieve its intended result. The term "patient" or "subject" refers to animals, including mammals, preferably humans, who are treated with the pharmaceutical compositions or in accordance with the 10 methods described herein. A "stem cell" as used herein refers undifferentiated cells defined by the ability of a single cell both to self- renew, and to differentiate to produce progeny cells, including self renewing progenitors, non- renewing progenitors, and terminally differentiated cells. Stem cells are also characterized by their ability to differentiate in vitro into functional 15 cells of various cell lineages from multiple germ layers (endoderm, mesoderm and ectoderm), as well as to give rise to tissues of multiple germ layers following transplantation, and to contribute substantially to most, if not all, tissues following injection into blastocysts. Stem cells may be totipotent, pluripotent, multipotent, oligopotent, or unipotent. 20 Totipotent cells are able to give rise to all embryonic and extraembryonic cell types. Pluripotent cells are able to give rise to all embryonic cell types. Multipotent cells include those able to give rise to a subset of cell lineages, but all within a particular tissue, organ, or physiological system (for example, hematopoietic stem cells (HSC) can produce progeny that include HSC (self-renewal), blood cell-restricted oligopotent 25 progenitors, and all cell types and elements (e.g., platelets) that are normal components of the blood). Cells that are oligopotent can give rise to a more restricted subset of cell lineages than multipotent stem cells; and cells that are unipotent are able to give rise to a single cell lineage (e.g., spermatogenic stem cells). Stem cells are also categorized on the 12 WO 2006/133052 PCT/US2006/021671 basis of the source from which they may be obtained. An adult stem cell is generally a multipotent undifferentiated cell found in tissue comprising multiple differentiated cell types. The adult stem cell can renew itself. Under normal circumstances, it can also differentiate to yield the specialized cell types of the tissue from which it originated, and 5 possibly other tissue types. "Mesenchymal stem cell" ("MSC") refers to a cell originating from the mesoderm of a mammal that is not fully differentiated and has the potential to differentiate into a variety of cells or tissues, including: connective tissue, bone, and cartilage, muscle, blood and blood vessels, lymphatic and lymphoid organs, notochord, pleura, pericardium, kidney, 10 and gonads. A "progenitor cell" refers to a cell that is derived from a stem cell by differentiation and is capable of further differentiation to more mature cell types. Progenitor cells typically have more restricted proliferation capacity as compared to stem cells. By "conditioned media" is meant that a population of cells in grown in a medium and 15 contribute soluble factors to the medium. In one such use, the cells are removed from the medium however the soluble factors produced by these cells remain. This medium is then used to nourish a different population of cells in the presence of the soluble factors produced by the initial population of cells. "Markers" as used herein, are nucleic acid or polypeptide molecules that are differentially 20 expressed in a cell of interest. In this context, differential expression means an increased level of the marker for a positive marker, and a decreased level for a negative marker. The detectable level of the marker nucleic acid or polypeptide is sufficiently higher or lower in the cells of interest, compared to other cells, such that the cell of interest can be identified and distinguished from other cells, using any of a variety of methods known in the art. 25 "Cluster of Differentiation" (CD) molecules are markers on the cell surface, as recognized by specific sets of antibodies, used to identify the cell type, stage of differentiation and activity state of a cell. Function and designation of CD markers are 13 WO 2006/133052 PCT/US2006/021671 well established in the art. See, e.g., The Leukocyte Antigen Fact Book, 2 nd edition, Barclay, A. N. et al. Academic Press, London 1997. "CD14" is is a high affinity receptor for the complex of lipopolysaccharids (LPS) and LPS-Binding protein (LBP). The CD14 antigen is part of the functional heteromeric LPS 5 receptor complex comprised of CD14, TLR4 and MD-2. CD14 is strongly expressed on most human monocytes and macrophages in peripheral blood, other body fluids and various tissues, such as lymph nodes and spleen. CD14 is weakly expressed on subpopulations of human neutrophils and myeloid dendritic cells. "CD29" is also referred to as " fibronectin receptor, beta polypeptide". 10 "CD34" is a transmembrane glycoprotein constitutively expressed on endothelial cells and on hematopoietic stem cells. This highly O-glycosylated molecule, containing serine and threonine-rich mucin like domains, binds to L-selectin. "CD44" is also referred to as "Hermes antigen" and is the main cell surface receptor for hyaluronan. This CD is primarily expressed in most cell types, except for tissues/cells 15 such as hepatocytes, some epithelial cells, and cardiac muscle. "CD45" refers to the leukocyte common antigen having a sequence disclosed in Genbank Accession No. Y00638, or a naturally occurring variant sequence thereof (e.g., allelic variant). "CD105" is also referred to as "Endoglin" and is primarily expressed on endothelial cells, 20 monocytes, macrophages, stromal cells, and bone marrow mesenchymal cells. "CD166" is a type 1 glycoprotein expressed on activated T cells, B cells and monocytes and appears to be the ligand for CD6 (1,2). Human CD166 may be important for activation of T cells. The term "pharmaceutically acceptable carrier" (or "medium"), which may be used 25 interchangeably with the term "biologically compatible carrier" or "medium", refers to reagents, cells, compounds, materials, compositions, and/or dosage forms that are not 14 WO 2006/133052 PCT/US2006/021671 only compatible with the cells and other agents to be administered therapeutically, but also are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other complication commensurate with a reasonable benefit/risk ratio. 5 Several terms are used herein with respect to cell replacement therapy. The terms "autologous transfer", "autologous transplantation", "autograft" and the like, refer to treatments wherein the cell donor is also the recipient of the cell replacement therapy. The terms "allogeneic transfer", "allogeneic transplantation", "allograft" and the like, refer to treatments wherein the cell donor is of the same species as the recipient of the 10 cell replacement therapy, but is not the same individual. A cell transfer in which the donor's cells and have been histocompatibly matched with a recipient is sometimes referred to as a "syngeneic transfer". The terms "xenogeneic transfer", "xenogeneic transplantation", "xenograft" and the like, refer to treatments wherein the cell donor is of a different species than the recipient of the cell replacement therapy. 15 Isolation and Characterization of Mesenchymal Stem Cells. Mesenchymal stem cells suitable for use in the methods of the present invention may be obtained from tissues such as, for example, bone marrow, umbilical cord blood, amniotic sac, amniotic fluid, placenta, skin, fat, muscle, vasculature, liver, pancreas, or peripheral blood, using methods that are well known in the art. Isolation of a population of 20 mesenchymal stem cells may be achieved using monoclonal antibodies specific proteins expressed on the surface of MSC's. The monoclonal antibodies may be adhered to substrate to facilitate the separation of the bound cells. The methods that may be used to isolate MSC's suitable for use in the present invention may be chosen by one of ordinary skill in the art. Examples of such methods are taught in US6087113, US6261549, 25 US5914262, US5908782, and US20040058412. MSC's may be characterized, for example, by growth characteristics (e.g., population doubling capability, doubling time, passages to senescence), karyotype analysis (e.g., normal karyotype; maternal or neonatal lineage), flow cytometry (e.g., FACS analysis), 15 WO 2006/133052 PCT/US2006/021671 immunohistochemistry and/or immunocytochemnistry (e.g., for detection of epitopes), gene expression profiling (e.g., gene chip arrays; polymerase chain reaction (for example, reverse transcriptase PCR, real time PCR, and conventional PCR)), protein arrays, protein secretion - 19 (e.g., by plasma clotting assay or analysis of PDC-conditioned 5 medium, for example, by Enzyme Linked Immuno-Sorbent Assay (ELISA)), mixed lymphocyte reaction (e.g., as measure of stimulation of PBMCs), and/or other methods known in the art. Mesenchymal stem cells suitable for use in the methods of the present invention may also include cells obtained from commercial sources, such as, for example human 10 mesenchymal stem cells sold under the trade name POIETICSTM (Cat. No PT-2501, Cambrex). These mesenchymal stem cells are positive for the expression of the following markers: CD29, CD44, CD105 and CD166. The cells are negative for the expression of the markers CD14, CD34 and CD45. Isolated MSC's, or tissue from which MSC's are obtained may be used to initiate, or 15 seed, cell cultures. Isolated cells may be transferred to sterile tissue culture vessels, either uncoated or coated with extracellular matrix or ligands such as laminin, collagen (native, denatured or crosslinked), gelatin, fibronectin, and other extracellular matrix proteins. MSC's may be cultured in any culture medium capable of sustaining growth of the cells such as, for example, DMEM (high or low glucose), advanced DMEM, 20 DMEM/MCDB 201, Eagle's basal medium, Ham's F10 medium (F10), Ham's F-12 medium (F12), Iscove's modified Dulbecco's - 17 medium, Mesenchymal Stem Cell Growth Medium (MSCGM), DMEM/F12, RPMI 1640, and CELL-GRO-FREE. The culture medium may be supplemented with one or more components including, for example, fetal bovine serum (FBS); equine serum (ES); human serum(HS); beta 25 mercaptoethanol (BME or 2-ME), preferably about 0.001% (v/v); one or more growth factors, for example, platelet-derived growth factor (PDGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1), leukocyte inhibitory factor (LIF) and erythropoietin; amino acids, including L-valine; and one or more antibiotic and/or antimycotic agents to 30 control microbial contamination, such as, for example, penicillin G. streptomycin sulfate, 16 WO 2006/133052 PCT/US2006/021671 amphotericin B. gentamicin, and nystatin, either alone or in combination. The cells may be seeded in culture vessels at a density to allow cell growth. Methods for the selection of the most appropriate culture medium, medium preparation, and cell culture techniques are well known in the art and are described in a variety of 5 sources, including Doyle et al., (eds.), 1995, CELL &TISSUE CULTURE: LABORATORY PROCEDURES, John Wiley &Sons, Chichester; and Ho and Wang (eds.), 1991, ANIMAL CELL BIOREACTORS, Butterworth-Heinemann, Boston. Use of Mesenchymal Stem Cells to treat Ophthalmic Disease. In one aspect of the present invention, MSC's are used as a cell therapy for treating an 10 ocular degenerative condition. Once transplanted into a target location in the eye, MSC's may provide trophic support for ocular cells in situ, or they may themselves differentiate into one or more phenotypes, or they may exert a beneficial effect in both of those fashions, among others. MSC's may be administered alone (e.g., as substantially homogeneous populations) or as 15 mixtures with other cells. MSC's may be administered in a pharmaceutical preparation, using conventional pharmaceutically acceptable carriers. Where MSC's are administered with other cells, they may be administered simultaneously or sequentially with the other cells (either before or after the other cells). Cells that may be administered in conjunction with MSC's include, but are not limited to, neurons, astrocytes, oligodendrocytes, neural 20 progenitor cells, neural stem cells, ocular progenitor cells, retinal or corneal epithelial stem cells and/or other multipotent or pluripotent stem cells. The cells of different types may be mixed with the MSC's immediately or shortly prior to administration, or they may be co-cultured together for a period of time prior to administration. The MSC's may be administered with at least one pharmaceutical agent, such as, for 25 example, growth factors, trophic factors, conditioned medium, or other active agents, such as anti-inflammatory agents, anti apoptotic agents, antioxidants, neurotrophic factors or neuroregenerative or neuroprotective drugs as known in the art. When MSC's are administered with other agents, they may be administered together in a single 17 WO 2006/133052 PCT/US2006/021671 pharmaceutical composition, or in separate pharmaceutical compositions, simultaneously or sequentially with the other agents (either before or after administration of the other agents). Examples of other components that may be administered with mesenchymal stem cells 5 include, but are not limited to: (1) other neuroprotective or neurobeneficial drugs; (2) selected extracellular matrix components, such as one or more types of collagen known in the art, and/or growth factors, platelet-rich plasma, and drugs (alternatively, the cells may be genetically engineered to express and produce growth factors); (3) anti- apoptotic agents (e.g., erythropoietin (EPO), EPO mimetibody, thrombopoietin, insulin-like growth 10 factor (IGF)-I, IGF-II, hepatocyte growth factor, caspase inhibitors); (4) anti inflammatory compounds (e.g., p38 MAP kinase inhibitors, TGF-beta inhibitors, stating, IL-6 and IL-1 inhibitors, PEMIROLAST, TRANILAST, REMICADE, SIROLIMUS, and non-steroidal anti-inflammatory drugs (NSAIDS) (such as - 36 TEPOXALIN, TOLMETIN, and SUPROFEN); (5) immunosuppressive or immunomodulatory agents, 15 such as calcineurin inhibitors, mTOR inhibitors, antiproliferatives, corticosteroids and various antibodies; (6) antioxidants such as probucol, vitamins C and E, conenzyme Q 10, glutathione, L-cysteine and N- acetylcysteine; and (6) local anesthetics, to name a few. In one embodiment, MSC's may be administered as undifferentiated cells, i.e., as 20 cultured in Growth Medium. Alternatively, MSC's may be administered following exposure in culture to conditions that stimulate differentiation toward a desired phenotype. The cells may be surgically implanted, injected or otherwise administered directly or indirectly to the site of ocular damage or distress. When cells are administered in semi-solid or solid devices, surgical implantation into a precise location in the body is 25 typically a suitable means of administration. Liquid or fluid pharmaceutical compositions, however, may be administered to a more general location in the eye (e.g., topically or intra-ocularly). Other embodiments encompass methods of treating ocular degenerative conditions by administering pharmaceutical compositions comprising MSC cellular components (e.g., 18 WO 2006/133052 PCT/US2006/021671 cell lysates or components thereof) or products (e.g., trophic and other biological factors produced naturally by MSC's or through genetic modification, conditioned medium from MSC culture). Again, these methods may further comprise administering other active agents, such as 5 growth factors, neurotrophic factors or neuroregenerative or neuroprotective drugs as known in the art. Dosage forms and regimes for administering MSC's or any of the other pharmaceutical compositions described herein are developed in accordance with good medical practice, taking into account the condition of the individual patient, e.g., nature and extent of the 10 ocular degenerative condition, age, sex, body weight and general medical condition, and other factors known to medical practitioners. Thus, the effective amount of a pharmaceutical composition to be administered to a patient is determined by these considerations as known in the art. It may be desirable or appropriate to pharmacologically immunosuppress a patient prior 15 to initiating cell therapy. This may be accomplished through the use of systemic or local immunosuppressive agents, or it may be accomplished by delivering the cells in an encapsulated device. These and other means for reducing or eliminating an immune response to the transplanted cells are known in the art. As an alternative, MSC's may be genetically modified to reduce their immunogenicity. 20 According to another aspect of the invention, a method is provided for treating a patient having an ocular degenerative condition, which may comprise administering to the patient a preparation made from mesenchymal stem cells, in an amount effective to treat the ocular degenerative condition, wherein the preparation comprises a cell lysate of the MSC's, or a conditioned medium in which the MSC's were grown, or an extracellular 25 matrix of the MSC's. The lysate may comprise at least one or all of the sub-cellular fractions of the MSC's, such as, for example the plasma membrane fraction. Methods of lysing cells are well known in the art and include various means of mechanical disruption, enzymatic disruption, or chemical disruption, or combinations thereof. Such 19 WO 2006/133052 PCT/US2006/021671 cell lysates may be prepared from cells directly in their growth medium and thus containing secreted growth factors and the like, or may be prepared from cells washed free of medium in, for example, PBS or other solution. Washed cells may be resuspended at concentrations greater than the original population density if preferred. In 5 one embodiment, whole cell lysates may be prepared, e.g., by disrupting cells without subsequent separation of cell fractions. In another embodiment, a cell membrane fraction is separated from a soluble fraction of the cells by routine methods known in the art, e.g., centrifugation, filtration, or similar methods. Cell lysates or cell soluble fractions prepared from populations of MSC's may be used as 10 is, further concentrated, by for example, ultrafiltration or lyophilization, or even dried, partially purified, combined with pharmaceutically-acceptable carriers or diluents as are known in the art, or combined with other compounds such as biologicals, for example pharmaceutically useful protein compositions. Cell lysates or fractions thereof may be used in vitro or in vivo, alone or for example, with autologous or allogenic live cells. The 15 lysates, if introduced in vivo, may be introduced locally at a site of treatment, or remotely to provide, for example needed cellular growth factors to a patient. In another aspect, the invention features a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a preparation made from the mesenchymal stem cells, which may be a lysate of the MSC's, an extracellular matrix of the MSC's or a 20 conditioned medium in which MSC's were grown. Kits for practicing this aspect of the invention are also provided. These may include the one or more of a pharmaceutically acceptable carrier or other agent or reagent, one or more of a cell lysate or fraction thereof, an extracellular matrix or a conditioned medium from the MSC's, and instructions for use of the kit components. 25 Pharmaceutical formulations. Pharmaceutical compositions of the invention may comprise postpartum cells MSC's, or components or products thereof, formulated with a pharmaceutically acceptable carrier or medium. Suitable pharmaceutically acceptable carriers include water, salt solution (such 20 WO 2006/133052 PCT/US2006/021671 as Ringer's solution), alcohols, oils, gelatins, and carbohydrates, such as lactose, amylose, or starch, fatty acid esters, hydroxymethylcellulose, and polyvinyl pyrolidine. Such preparations may be sterilized, and if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing 5 osmotic pressure, buffers, and coloring. Typically, but not exclusively, pharmaceutical compositions comprising cellular components or products, but not live cells, are formulated as liquids. Pharmaceutical compositions comprising live MSC's are typically formulated as liquids, semisolids (e.g., gels) or solids (e.g., matrices, supports and the like, as appropriate for ophthalmic tissue engineering). 10 Pharmaceutical compositions may comprise auxiliary components as would be familiar to medicinal chemists or biologists. For example, they may contain antioxidants in ranges that vary depending on the kind of antioxidant used. Reasonable ranges for commonly used antioxidants are about 0.01% to about 0.15% weight by volume of EDTA, about 0.01% to about 2.0% weight volume of sodium sulfite, and about 0.01% to about 2.0% 15 weight by volume of sodium metabisulfite. One skilled in the art may use a concentration of about 0.1% weight by volume for each of the above. Other representative compounds include mercaptopropionyl glycine, N- acetyl cysteine, beta mercaptoethylamine, glutathione and similar species, although other anti- oxidant agents suitable for ocular administration, e.g. ascorbic acid and its salts or sulfite or sodium 20 metabisulfite may also be employed. A buffering agent may be used to maintain the pH of eye drop formulations in the range of about 4.0 to about 8.0; so as to minimize irritation of the eye. For direct intravitreal or intraocular injection, formulations should be at pH 7.2 to 7.5, alternatively at pH 7.3-7.4. The ophthalmologic compositions may also include tonicity agents suitable for 25 administration to the eye. Among those suitable is sodium chloride to make formulations approximately isotonic with 0.9% saline solution. In certain embodiments, pharmaceutical compositions are formulated with viscosity enhancing agents. Such agents can be, for example, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, and polyvinylpyrrolidone. The pharmaceutical 21 WO 2006/133052 PCT/US2006/021671 compositions may have co-solvents added if needed. Suitable co-solvents may include glycerin, polyethylene glycol (PEG), polysorbate, propylene glycol, and polyvinyl alcohol. Preservatives may also be included, such as, for example, benzalkonium chloride, benzethonium chloride, chlorobutanol, phenylmercuric acetate or nitrate, 5 thimerosal, or methyl or propylparabens. Formulations for injection may be designed for single-use administration and do not contain preservatives. Injectable solutions nay have isotonicity equivalent to 0.9% sodium chloride solution (osmolality of 290-300 milliosmoles). This may be attained by addition of sodium chloride or other co-solvents as listed above, or excipients such as 10 buffering agents and antioxidants, as listed above. The tissues of the anterior chamber of the eye are bathed by the aqueous humor, while the retina is under continuous exposure to the vitreous. These fluids/gels exist in a highly reduced state because they contains antioxidant compounds and enzymes. Therefore, it may be advantageous to include a reducing agent in the ophthalmologic compositions. 15 Suitable reducing agents include N-acetylcysteine, ascorbic acid or a salt form, and sodium sulfite or metabisulfite, with ascorbic acid and/or N-acetylcysteine or glutathione being particularly suitable for injectable solutions. Pharmaceutical compositions comprising cells, cell components or cell products may be delivered to the eye of a patient in one or more of several delivery modes known in the 20 art. In one embodiment that may be suitable for use in some instances, the compositions are topically delivered to the eye in eye drops or washes. In another embodiment, the compositions may be delivered to various locations within the eye via periodic intraocular injection or by infusion in an irrigating solution such as BSS or BSS PLUS (Alcon USA, Fort Worth, TX). Alternatively, the compositions may be applied in other 25 ophthalmologic dosage forms known to those skilled in the art, such as pre-formed or in situ-formed gels or liposomes, for example as disclosed in U.S. Patent 5,718,922 to Herrero- Vanrell. In another embodiment, the composition may be delivered to or through the lens of an eye in need of treatment via a contact lens (e.g. Lidofilcon B. Bausch &Lomb CW79 or DELTACON (Deltafilcon A) or other object temporarily 22 WO 2006/133052 PCT/US2006/021671 resident upon the surface of the eye. In other embodiments, supports such as a collagen corneal shield (e.g. BIO- COR dissolvable corneal shields, Summit Technology, Watertown, Mass.) may be employed. The compositions may also be administered by infusion into the eyeball, either through a 5 cannula from an osmotic pump (ALZET, Alza Corp., Palo Alto, Calif.) or by implantation of timed- release capsules (OCCUSENT) or biodegradable disks (OCULEX, OCUSERT). These routes of administration have the advantage of providing a continuous supply of the pharmaceutical composition to the eye. This may be an advantage for local delivery to the cornea, for example. 10 Pharmaceutical compositions comprising live cells in a semi-solid or solid carrier are typically formulated for surgical implantation at the site of ocular damage or distress. It will be appreciated that liquid compositions also may be administered by surgical procedures. In particular embodiments, semi-solid or solid pharmaceutical compositions may comprise semi permeable gels, lattices, cellular supports and the like, which may be 15 non-biodegradable or biodegradable. For example, in certain embodiments, it may be desirable or appropriate to sequester the exogenous cells from their surroundings, yet enable the cells to secrete and deliver biological molecules to surrounding cells. In these embodiments, cells may be formulated as autonomous implants comprising living MSC's or cell population comprising MSC's surrounded by a non- degradable, selectively 20 permeable barrier that physically separates the transplanted cells from host tissue. Such implants are sometimes referred to as "immunoprotective," as they have the capacity to prevent immune cells and macromolecules from killing the transplanted cells in the absence of pharmacologically induced immunosuppression (for a review of such devices and methods, see, e.g., P.A. Tresco et al., 2000, Adv. Drug Delivery Rev. 42: 3-27). 25 Supports. In one aspect, the MSC's of the present invention may be incorporated into a support material prior to transplantation. Support materials suitable for use for purposes of the present invention include tissue templates, conduits, barriers, and reservoirs useful for 23 WO 2006/133052 PCT/US2006/021671 tissue repair. In particular, synthetic and natural materials in the form of foams, sponges, gels, hydrogels, textiles, and nonwoven structures, which have been used in vitro and in vivo to reconstruct or regenerate biological tissue, as well as to deliver chemotactic agents for inducing tissue growth, are suitable for use in practicing the methods of the present 5 invention. See, e.g., the materials disclosed in U.S. Patent 5,770,417, U.S. Patent 6,022,743, U.S. Patent 5,567,612, U.S. Patent 5,759,830, U.S. Patent 6,626,950, U.S. Patent 6,534,084, U.S. Patent 6,306,424, U.S. Patent 6,365,149, U.S. Patent 6,599,323, U.S. Patent 6,656,488, and U.S. Patent 6,333,029. Exemplary polymers suitable for use in the present invention are disclosed in U.S. Published Application 2004/0062753 Al 10 and U.S. Patent 4,557,264. To form a support incorporated with a pharmaceutical agent, the pharmaceutical agent may be mixed with the polymer solution prior to forming the support. Alternatively, a pharmaceutical agent may be coated onto a fabricated support, preferably in the presence of a pharmaceutical carrier. The pharmaceutical agent may be present as a liquid, a 15 finely divided solid, or any other appropriate physical form. Alternatively, excipients may be added to the support to alter the release rate of the pharmaceutical agent. In an alternate embodiment, the support is incorporated with at least one pharmaceutical compound that is an anti-inflammatory compound, such as, for example compounds disclosed in U.S. Patent 6,509,369. 20 In one embodiment, the support is incorporated with at least one pharmaceutical compound that is an anti-apoptotic compound, such as, for example, compounds disclosed in U.S. Patent 6,793,945. In another embodiment, the support is incorporated with at least one pharmaceutical compound that is an inhibitor of fibrosis, such as, for example, compounds disclosed in 25 U.S. Patent 6,331,298. In a further embodiment, the support is incorporated with at least one pharmaceutical compound that is capable of enhancing angiogenesis, such as, for example, compounds 24 WO 2006/133052 PCT/US2006/021671 disclosed in U.S. Published Application 2004/0220393 and U.S. Published Application 2004/0209901. In still another embodiment, the support is incorporated with at least one pharmaceutical compound that is an immunosuppressive compound, such as, for example, compounds 5 disclosed in U.S. Published Application 2004/0171623. In a further embodiment, the support is incorporated with at least one pharmaceutical compound that is a growth factor, such as, for example, members of the TGF-03 family, including TGF-P1, 2, and 3, bone morphogenic proteins (BMP-2, -3, -4, -5, -6, -7, -11, 12, and -13), fibroblast growth factors-1 and -2, platelet-derived growth factor-AA, and 10 BB, platelet rich plasma, insulin growth factor (IGF-I, II) growth differentiation factor (GDF-5, -6, -8, -10, -15), vascular endothelial cell-derived growth factor (VEGF), pleiotrophin, endothelin, among others. Other pharmaceutical compounds can include, for example, nicotinamide, hypoxia inducible factor 1-alpha, glucagon like peptide-I (GLP-1), GLP-1 and GLP-2 mimetibody, and II, Exendin-4, retinoic acid, parathyroid 15 hormone, tenascin-C, tropoelastin, thrombin-derived peptides, cathelicidins, defensins, laminin, biological peptides containing cell- and heparin-binding domains of adhesive extracellular matrix proteins such as fibronectin and vitronectin, MAPK inhibitors, such as, for example, compounds disclosed in U.S. Published Application 2004/0209901 and U.S. Published Application 2004/0132729. 20 The incorporation of the cells of the present invention into a support may be achieved by the simple depositing of cells onto the support. Cells may enter into the support by simple diffusion (J. Pediatr. Surg. 23 (1 Pt 2): 3-9 (1988)). Several other approaches have been developed to enhance the efficiency of cell seeding. For example, spinner flasks have been used in seeding of chondrocytes onto polyglycolic acid supports 25 (Biotechnol. Prog. 14(2): 193-202 (1998)). Another approach for seeding cells is the use of centrifugation, which yields minimum stress to the seeded cells and enhances seeding efficiency. For example, Yang et al. developed a cell seeding method (J. Biomed. Mater. Res. 55(3): 379-86 (2001)), referred to as Centrifugational Cell Immobilization (CCI). 25 WO 2006/133052 PCT/US2006/021671 Survival of transplanted cells in a living patient may be determined through the use of a variety of scanning techniques, e.g., computerized axial tomography (CAT or CT) scan, magnetic resonance imaging (MRI) or positron emission tomography (PET) scans. Determination of transplant survival may also be done post mortem by removing the 5 tissue and examining it visually or through a microscope. Alternatively, cells may be treated with stains that are specific for neural or ocular cells or products thereof, e.g., neurotransmitters. Transplanted cells may also be identified by prior incorporation of tracer dyes such as rhodamine- or fluorescein-labeled microspheres, fast blue, ferric microparticles, bisbenzamide or genetically introduced reporter gene products, such as 10 beta-galactosidase or beta-glucuronidase. Examining restoration of the ocular function that was damaged or diseased can assess functional integration of transplanted cells into ocular tissue of a subject. For example, effectiveness in the treatment of macular degeneration or other retinopathies may be determined by improvement of visual acuity and evaluation for abnormalities and grading 15 of stereoscopic color fundus photographs (Age- Related Eye Disease Study Research Group, NEI, NIH, AREDS Report No. 8, 2001, Arch. Ophthalmol. 119: 1417-1436). The present invention is further illustrated, but not limited by, the following examples. EXAMPLE USE OF MESENCHYMAL STEM CELLS IN THE TREATMENT OF RETINITIS 20 PIGMENTOSA Royal College of Surgeon (RCS) rats are genetically predisposed to undergo significant visual loss caused by a primary dysfunction of retinal pigment epithelial (RPE) cells. Using this model, the efficacy of subretinal transplantation of mesenchymal stem cell populations to preserve photoreceptors in RCS rats was tested. In this degenerative 25 model, rod function is lost within 30 to 60 days after birth. Loss of cone function usually follows within 3 months. 26 WO 2006/133052 PCT/US2006/021671 Preparation of MSC's for transplantation. Cultures of human adult MSC's (Cat. No. PT-2501, Cambrex) were expanded in vitro for a total of 6 passages. All cells were initially seeded at 5,000 cells/cm2 on non-coated T75 flasks in mesenchymal stem cell growth medium supplemented according to the 5 manufacturer's instructions (Cambrex). For subsequent passages all cells were treated as follows. After trypsinization, viable cells were counted after trypan Blue staining. Briefly, 50 ml of cell suspension was combined with 50 ml of 0.04% w/v trypan Blue (Sigma, St. Louis MO) and the viable cell number, was estimated using a heamocytometer. Cells were trypsinized and washed three times in supplement free 10 DMEM:Low glucose medium (Invitrogen, Carlsbad, CA). Cultures of human MSCs cells at passage 6 were trypsinized and washed twice in Leibovitz's L-15 medium (Invitrogen, Carlsbad, CA), to remove serum components. For the transplantation procedure dystrophic RCS rats were anesthetized with xylazine-ketamine (1 mg/kg i.p. of the following mixture: 2.5 ml xylazine at 20 mg/ml, 5 ml ketamine at 100 mg/ml, and 0.5 15 ml distilled water) and their head secured by a nose bar. Cells devoid of serum were resuspended (2 X 104 cells per injection) in 2 ml of Leibovitz, L-15 medium (Invitrogen, Carlsbad, CA) and transplanted using a fine glass pipette (internal diameter 75 - 150 mrn) trans-scerally. Cells were delivered into the dorso-temporal subretinal space of anesthetized 3 week old dystrophic-pigmented RCS rats (total N= 10/cell type). 20 Cells were injected unilaterally into the right eye, whilst the left eye was injected with carrier medium alone (Sham control; Leibovitz's L-15 medium). Viability of residual un-injected cells remained at greater than 95% as assessed by trypan blue exclusion at the completion of cell injections. After cell injections were performed animals were injected with dexamethasone (2 mg/kg) for 10 days post transplantation. For the duration of the 25 study animals were maintained on oral cyclosporine A (210 mg/L of drinking water; resulting blood concentration: 250-300 mg/L) (Bedford Labs, Bedford, Ohio) from 2 days pre-transplantation until end of the study. Food and water were available ad libitum. Animals were sacrificed at 60 or 90 days postoperatively with the remainder of animals being sacrificed at earlier time-points for histological assessment of short-term changes 30 associated with cell transplantation. 27 WO 2006/133052 PCT/US2006/021671 The ability of other cell types to treat the ocular degeneration observed in RCS rats was also tested. Cellular compositions were prepared from human umbilical-derived cells (cells disclosed in published U.S. Patent Application US2005/0054098), human placental-derived cells (cells disclosed in published U.S. Patent Application 5 US2005/0058631) and fibroblasts. The cellular compositions were administered to parallel groups pf animals according to the methods described above. Functional assays. Electroretinogram Recordings: The electroretinogram (ERG) is a recording of electrical potentials (action potentials) that are generated within the retina (typically in response to 10 a flash of light). It is recorded using two electrodes, with one electrode placed on or close to the cornea of the eye whilst the other is placed on the scalp. Following overnight dark adaptation, animals were prepared for ERG recording under dim red light, as described in Sauve et al, 2004. In brief, under anesthesia (with a mixture of 150 mg/kg i.p ketamine, and 10 mg/kg i.p. xylazine) the head was secured with a stereotaxic head 15 holder and the body temperature monitored through a rectal thermometer and maintained at 38 'C using a homeothermic blanket. Pupils were dilated using equal parts of topical 2.5 % phenylephrine and 1 % tropicamide. Topical anesthesia with 0.75 % bupivacaine was used to prevent any corneal reflexes and a drop of 0.9 % saline was frequently applied on the cornea to prevent its dehydration and allow electrical contact with the 20 recording electrode (gold wire loop). A 25-gauge needle inserted under the scalp, between the two eyes, served as the reference electrode. Amplification (at 1-1000 Hz bandpass, without notch filtering), stimulus presentation, and data acquisition were provided by the UTAS-3000 system from LKC Technologies (Gaithersburg, MD). A double flash protocol was used to determine the isolation of rod and cone responses 25 (Nixon et al, 2001). A probe flash was presented 1 sec after a conditioning flash, using a specific feature of the UTAS-3000 system (LKC Technologies) with calibrated ganzfeld; assuring complete recharge of the stimulator. The role of the conditioning flash in this procedure was to transiently saturate rods so that they were rendered unresponsive to the probe flash. Response to the probe flash was taken as reflecting cone-driven activity (a 28 WO 2006/133052 PCT/US2006/021671 wave). A rod-driven b-wave was obtained by subtracting the cone-driven response from the mixed response (obtained following presentation of a probe flash alone, i.e. not preceded by any conditioning flash). For the quantification of dark-adapted b-waves, recordings consisted of single flash 5 presentations (10 psec duration), repeated 3 to 5 times to verify the response reliability and improve the signal-to-noise ratio, if required. Stimuli were presented at six increasing intensities in one log unit steps varying from -3.6 to 1.4 log candila/m2 in luminance. To minimize the potential bleaching of rods, inter-stimulus intervals were increased as the stimulus luminance was elevated from 10 sec at lowest stimulus intensity 10 up to 2 minutes at highest stimulus intensity. The maximum b-wave amplitude was defined as that obtained from the flash intensity series, regardless of the stimulus intensity (Nusinowitz et al, 1999). Animals that received umbilical cell injections (n=6) demonstrated improvement in all outcome measures tested at 60 days , a-wave (27 + 11) versus sham controls (0), mixed 15 b-wave (117 + 67) versus sham controls (18 + 13), cone-b-wave (55 + 25) versus sham controls (28 + 11), and in rod contribution (49 + 16 %) versus sham controls (6 + 7 %). Furthermore, at 90 days improved responses were measured in 2 animals tested with measures being, a-wave (15 + 7) versus sham controls (0), mixed b-wave (37 + 15) versus sham controls (0), cone-b-wave (16 + 11) versus sham controls (7 + 5), and in rod 20 contribution (58 + 39 %) versus sham controls (0 %). (Figure 1). The response observed in these animals was much greater than that seen with un-treated or sham treated animals. MSC injections (n=5) at 58 days showed responsiveness to a-wave measurements (16.4 + 13.1) versus sham controls (14.6 + 12.5). Functional preservation of vision was demonstrated in mixed b-wave responsiveness (81.6 + 15.3) versus shams (54.4 + 24.5), 25 and in isolated cone-b-wave responsiveness (134 + 68) versus shams (72.4 + 40.8), and in overall measures of rod contribution (41 + 16.8) versus shams (21 + 19.34). These results demonstrated demonstrate preservation of photoreceptor function at 60 days in these animals. 29 WO 2006/133052 PCT/US2006/021671 MSC injections (n=5) at 88 days in the same animals demonstrated significant preservation in all the ERG measures when compared to sham controls. Responsiveness to a-wave measurements (14.3 + 12.1) versus sham controls (0). Functional preservation of vision was demonstrated in mixed b-wave responsiveness (64.5 + 24) versus shams 5 (0), and in isolated cone-b-wave responsiveness (32.6 + 22.7) versus shams (8 + 4), and in overall measures of rod contribution (47.5 + 29) versus shams (0). These results demonstrated improvement in visual responsiveness when compared to sham controls. Thus, the data clearly demonstrates that visual function is preserved in RCS animals that receive MSC injections vs sham controls, where vision is lost by 90 days. 10 Placental cell transplants (n=4) at 60 days showed no improvement in a-wave (20 + 20) versus sham controls (0), but showed minor improvement in mixed b-wave (81 + 72) versus sham controls (1.5 + 2), and good improvement in cone-b-wave (50 + 19) versus sham controls (7 + 7), and in rod contribution (30 %) versus sham controls (0). These results indicated some improvement in visual responsiveness when compared to sham 15 controls. This suggests that photoreceptor rescue was observed in these animals to a small extent (Figure 1). In contrast, animals receiving fibroblast transplantations showed no improvement in any of the parameters tested. Functional Assessment: Physiological retinal sensitivity testing was performed to 20 demonstrate retinal response to dim light. In these tests animals were anesthetized with urethane at 1.25 g/kg i.p. Physiological assessment in these animals was tested post graft in animals at 90 days by recording multiunit extracellular activity in the superior colliculus to illumination of respective visual receptive fields (Lund et al, 2001). This procedure was repeated for 20 independent points (spaced 200 numm apart, with each step 25 corresponding to approximately 10-150 displacements in the visual field), covering the visual field. Visual thresholds were measured as the increase in intensity over background and maintained at 0.02 candila/m2 (luminescence unit), required for activating units in the superficial 200 mm of the superior colliculus with a spot of light 30 30 WO 2006/133052 PCT/US2006/021671 in diameter. Response parameters were compared between transplanted and sham control eyes that received vehicle alone. Visual acuity: The grating acuity of RCS rats was tested after 3 and 4 months of age months. Normal animals demonstrate acuity of 0.5 cycles/degree at 3 months of age. After 3 months eyes injected with MSCs maintained an average acuity of 0.47 cycles/degree (n = 14) in contrast to sham treated animals that retained an average acuity of 0.2 cycles/degree. Thus visual acuity was preserved in these animals 90 days post graft. At 4 months of age MSC grafted animals maintained an average acuity of 0.36 cycles/degree (n = 7), in contrast to sham treated animals that retained acuity at baseline levels (Figure 2). Visual Thresholds: Efficacy of transplants in preventing visual loss was monitored by assessment of electrophysiological responsiveness in 4 animals. The threshold sensitivity response to light was used to define the area of visual field rescue in sham-injected control eyes versus eyes transplanted with MSC's. In nondystrophic rats, visual thresholds never exceeded 0.5 log candila/m above background (Figure 3). In non operated dystrophic rats, the thresholds are usually in the magnitude of 4 log candila/m 2 units (Blakema and Drager, 1991). By contrast, in non-operated sham injected dystrophic rats, the thresholds were in the order of 2.9 -4.9 log candila/m 2 units with an average threshold of 4.0 log candila/m 2 units, in some instances no recording could be attained (Figure 3). Thus, the sham-injected rats showed some highly localized functional rescue in the temporal retina. However, the human MSC transplanted rats exhibited substantially greater levels of visual preservation with thresholds ranging from 0.8 to 2.1 log candila/m 2 units, with an average threshold of 1.3 log candila/m 2 units (Figure 3). On average 60% of threshold responses were below 2.1 log candela units in MSC injected animals vs. 18% in sham injected controls. Histology: At the conclusion of the study, animals were sacrificed with an overdose of urethane (12.5 g/kg). The orientation of the eye was maintained by placing a 6.0 suture through the superior rectus muscle prior to enucleation. After making a corneal incision, the eyes were fixed with 2.5 % parafomaldehyde, 2.5 % glutaraldehyde, 0.01 % picric 31 WO 2006/133052 PCT/US2006/021671 acid in 0.1 M cacodylate buffer (pH7.4). After fixation, the cornea and lens were removed by cutting around the cilliary body. A small nick was made in the periphery of the dorsal retina prior to removal of the superior rectus to assist in maintaining orientation. The retinas were then post-fixed in I % osmium tetroxide for 1 h. After 5 dehydration through a series of alcohols to epoxypropane, the retinas were embedded in TAAB embedding resin (TAAB Laboratories, Aldemarston, UK). Semi-thin sections were stained with 1% toluidine Blue in 1% borate buffer and the ultra thin sections were contrasted with uranyl acetate and lead citrate. For Nissl staining, sections were stained with 0.75% cresyl violet (Sigma, St. Louis, MO) 10 after which they were dehydrated through graded alcohols at 70, 95 and 100 % twice. They were then placed in xylene (Sigma, St. Louis, MO), rinsed with PBS (pH 7.4) (Invitrogen, Carlsbad, CA), coverslipped and mounted with DPX mountant (Sigma, St. Louis, MO). Histologicaly at the 90-100 day time point in MSC treated animals, anatomical rescue of 15 host photoreceptors was clearly demonstrated (Figure 4). The photoreceptors form a thick layer separated by a gap from the inner nuclear layer, made up of other retinal cells. The width of the outer layer in the sham control is at best a discontinuous single layer as opposed to around 3-5 cells thick in the grafted eye. In comparison to a normal animal this is marginally more than half the thickness of photoreceptor cell layers normally 20 observed. Publications cited throughout this document are hereby incorporated by reference in their entirety. Although the various aspects of the invention have been illustrated above by reference to examples and preferred embodiments, it will be appreciated that the scope of the invention is defined not by the foregoing description, but by the following claims 25 properly construed under principles of patent law. 32
    权利要求:
    Claims (31)
    [1] 1. A method of treating a patient having an ocular degenerative condition, the method comprising administering to the patient mesenchymal stem cells in an amount effective to treat the ocular degenerative condition, wherein the 5 mesenchymal stem cells are characterized by the expression of at least one of the following surface markers: CD29, CD44, CD105 or CD166, and the lack of expression of at least one of CD14, CD34 or CD45.
    [2] 2. The method of claim 1, wherein the mesenchymal stem cells promote the survival of ocular cells in situ but the cells do not form structures similar to the 10 photoreceptor layer and do not express a photoreceptor-specific marker.
    [3] 3. The method of claim 1, wherein the mesenchymal stem cells promote the formation of photoreceptors from ocular cells in situ but the stem cells do not differentiate into photoreceptors themselves.
    [4] 4. The method of claim 1, wherein the ocular degenerative condition is an acute 15 ocular degenerative condition.
    [5] 5. The method of claim 4, wherein the acute ocular degenerative condition is a brain trauma, optic nerve trauma or ocular lesion.
    [6] 6. The method of claim 1, wherein the ocular degenerative condition is a chronic or progressive degenerative condition. 20
    [7] 7. The method of claim 6, wherein the chronic or progressive ocular degenerative condition is macular degeneration, retinitis pigmentosa, diabetic retinopathy, glaucoma, limbal epithelial cell deficiency.
    [8] 8. The method of claim 1, wherein the cells are administered with at least one other cell type. 25
    [9] 9. The method of claim 8, wherein the at least one other cell type is an astrocyte, oligodendrocyte, neuron, neural progenitor, neural stem cell, retinal epithelial stem cell, corneal epithelial stem cell, or other multipotent or pluripotent stem cell.
    [10] 10. The method of claim 8, wherein the at least one other cell type is administered 30 simultaneously with, or before, or after, the mesenchymal stem cells. 33 WO 2006/133052 PCT/US2006/021671
    [11] 11. The method of claim 1, wherein the cells are administered with at least one other agent.
    [12] 12. The method of claim 11, wherein the at least one other agent is administered simultaneously with, or before, or after, the cells. 5
    [13] 13. The method of claim 1, wherein the cells are administered to the surface of an eye.
    [14] 14. The method of claim 1, wherein the cells are administered to the interior of an eye.
    [15] 15. The method of claim 14, wherein the cells are administered through a cannula or 10 from a device implanted in the patient's body within or in proximity to the eye.
    [16] 16. The method of claim 14, wherein the cells are administered by implantation of a three dimentional matrix or support containing the cells.
    [17] 17. A pharmaceutical composition for treating a patient having an ocular degenerative condition, the composition comprising mesenchymal stem cells in an amount 15 effective to treat the ocular degenerative condition, and a pharmaceutically acceptable carrier.
    [18] 18. The pharmaceutical composition of claim 17, wherein the mesenchymal stem cells are characterized by the expression of at least one of the following surface markers: CD29, CD44, CD105 or CD166, and the lack of expression of at least 20 one of CD14, CD34 or CD45.
    [19] 19. The pharmaceutical composition of claim 17 or 18, wherein the ocular degenerative condition is an acute ocular degenerative condition.
    [20] 20. The pharmaceutical composition of claim 19, wherein the acute ocular degenerative condition is a brain trauma, optic nerve trauma or ocular lesion. 25
    [21] 21. The pharmaceutical composition of claim 17 or 18, wherein the ocular degenerative condition is a chronic or progressive degenerative condition.
    [22] 22. The pharmaceutical composition of claim 21, wherein the chronic or progressive ocular degenerative condition is macular degeneration, retinitis pigmentosa, diabetic retinopathy, glaucoma, limbal epithelial cell deficiency. 30
    [23] 23. The pharmaceutical composition of claim 17 or 18, wherein the mesenchymal stem cells promote the survival of ocular cells in situ but the cells do not form 34 WO 2006/133052 PCT/US2006/021671 structures similar to the photoreceptor layer and do not express a photoreceptor specific marker.
    [24] 24. The pharmaceutical composition of claim 17 or 18, wherein the mesenchymal stem cells promote the formation of photoreceptors from ocular cells in situ but 5 the stem cells do not differentiate into photoreceptors themselves.
    [25] 25. The pharmaceutical composition of claim 17 or 18, containing at least one other cell type.
    [26] 26. The pharmaceutical composition of claim 25, wherein the at least one other cell type is an astrocyte, oligodendrocyte, neuron, neural progenitor, neural stem cell, 10 retinal epithelial stem cell, corneal epithelial stem cell, or other multipotent or pluripotent stem cell.
    [27] 27. The pharmaceutical composition of claim 25, comprising at least one other agent.
    [28] 28. The pharmaceutical composition of claim 27, wherein the at least one other agent is a drug for treating the ocular degenerative disorder. 15
    [29] 29. The pharmaceutical composition of claim 17 or 18, wherein the cells are administered to the surface of an eye.
    [30] 30. The pharmaceutical composition of claim 17 or 18, wherein the cells are administered to the interior of an eye.
    [31] 31. The pharmaceutical composition of claim 17 or 18, wherein the pharmaceutical 20 carrier is formulated as a three dimentional matrix or support containing the cells. 35
    类似技术:
    公开号 | 公开日 | 专利标题
    US20160030480A1|2016-02-04|Cellular Therapy for Ocular Degeneration
    JP4950660B2|2012-06-13|Repair and regeneration of ocular tissue using postpartum cells
    Liu et al.2017|Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients
    KR102073730B1|2020-02-05|Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
    ES2530370T5|2018-05-28|Retinal pigment epithelial cells derived from stem cells
    JP2010018627A|2010-01-28|Material from bone marrow stromal cell for use in forming blood vessel and producing angiogenic and trophic factors
    KR102359257B1|2022-02-07|How to treat retinal disease
    TW201908478A|2019-03-01|Method of modulating muller glia cells
    CN110913874A|2020-03-24|Method for measuring the efficacy of a retinal disease therapy
    JP2019501888A|2019-01-24|Treatment of retinal degeneration with progenitor cells
    TW201836623A|2018-10-16|Treatment of retinal degeneration using progenitor cells
    KR20170093178A|2017-08-14|Treatment of ocular conditions using progenitor cells
    JP2019524688A|2019-09-05|Treatment of retinal vascular disease using progenitor cells
    Nita et al.2012|Ophthalmic transplantology: Posterior segment of the eye–Part II
    KR20220020422A|2022-02-18|Methods of treating retinal diseases
    同族专利:
    公开号 | 公开日
    US20160030480A1|2016-02-04|
    US9074189B2|2015-07-07|
    SI1888123T1|2013-04-30|
    ES2400916T3|2013-04-15|
    US20060280729A1|2006-12-14|
    CN101484575A|2009-07-15|
    EP1888123B1|2013-01-09|
    PL1888123T3|2013-06-28|
    CA2613889A1|2006-12-14|
    CN101484575B|2013-10-02|
    WO2006133052A2|2006-12-14|
    JP2009500297A|2009-01-08|
    EP1888123A4|2009-04-29|
    WO2006133052A3|2008-11-20|
    EP1888123A2|2008-02-20|
    AU2006255183B2|2012-02-02|
    PT1888123E|2013-03-13|
    DK1888123T3|2013-04-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3209652A|1961-03-30|1965-10-05|Burgsmueller Karl|Thread whirling method|
    AT326803B|1968-08-26|1975-12-29|Binder Fa G|MESHWARE AND METHOD OF MANUFACTURING THE SAME|
    US3935067A|1974-11-22|1976-01-27|Wyo-Ben Products, Inc.|Inorganic support for culture media|
    CA1201400A|1982-04-16|1986-03-04|Joel L. Williams|Chemically specific surfaces for influencing cellactivity during culture|
    US4499802A|1982-09-29|1985-02-19|Container Graphics Corporation|Rotary cutting die with scrap ejection|
    US4537773A|1983-12-05|1985-08-27|E. I. Du Pont De Nemours And Company|α-Aminoboronic acid derivatives|
    US4557264A|1984-04-09|1985-12-10|Ethicon Inc.|Surgical filament from polypropylene blended with polyethylene|
    US5089396A|1985-10-03|1992-02-18|Genentech, Inc.|Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid|
    US5215893A|1985-10-03|1993-06-01|Genentech, Inc.|Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid|
    US4737578A|1986-02-10|1988-04-12|The Salk Institute For Biological Studies|Human inhibin|
    US5863531A|1986-04-18|1999-01-26|Advanced Tissue Sciences, Inc.|In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework|
    CA1340581C|1986-11-20|1999-06-08|Joseph P. Vacanti|Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices|
    US5804178A|1986-11-20|1998-09-08|Massachusetts Institute Of Technology|Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue|
    US5567612A|1986-11-20|1996-10-22|Massachusetts Institute Of Technology|Genitourinary cell-matrix structure for implantation into a human and a method of making|
    NZ229354A|1988-07-01|1990-09-26|Becton Dickinson Co|Treating polymer surfaces with a gas plasma and then applying a layer of endothelial cells to the surface|
    EP0363125A3|1988-10-03|1990-08-16|Hana Biologics Inc.|Proliferated pancreatic endocrine cell product and process|
    US5837539A|1990-11-16|1998-11-17|Osiris Therapeutics, Inc.|Monoclonal antibodies for human mesenchymal stem cells|
    KR100249937B1|1991-04-25|2000-04-01|나가야마 오사무|Reshaped human antibody to human interleukin-6 receptor|
    US5449383A|1992-03-18|1995-09-12|Chatelier; Ronald C.|Cell growth substrates|
    GB9206861D0|1992-03-28|1992-05-13|Univ Manchester|Wound healing and treatment of fibrotic disorders|
    CA2114282A1|1993-01-28|1994-07-29|Lothar Schilder|Multi-layered implant|
    JP3525221B2|1993-02-17|2004-05-10|味の素株式会社|Immunosuppressants|
    US5523226A|1993-05-14|1996-06-04|Biotechnology Research And Development Corp.|Transgenic swine compositions and methods|
    GB9310557D0|1993-05-21|1993-07-07|Smithkline Beecham Plc|Novel process and apparatus|
    TW257671B|1993-11-19|1995-09-21|Ciba Geigy||
    US6001647A|1994-04-28|1999-12-14|Ixion Biotechnology, Inc.|In vitro growth of functional islets of Langerhans and in vivo uses thereof|
    US6703017B1|1994-04-28|2004-03-09|Ixion Biotechnology, Inc.|Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures|
    US5834308A|1994-04-28|1998-11-10|University Of Florida Research Foundation, Inc.|In vitro growth of functional islets of Langerhans|
    US6083903A|1994-10-28|2000-07-04|Leukosite, Inc.|Boronic ester and acid compounds, synthesis and uses|
    EP0800829B2|1994-12-29|2012-07-25|Chugai Seiyaku Kabushiki Kaisha|Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin|
    US5843780A|1995-01-20|1998-12-01|Wisconsin Alumni Research Foundation|Primate embryonic stem cells|
    US5718922A|1995-05-31|1998-02-17|Schepens Eye Research Institute, Inc.|Intravitreal microsphere drug delivery and method of preparation|
    US5908782A|1995-06-05|1999-06-01|Osiris Therapeutics, Inc.|Chemically defined medium for human mesenchymal stem cells|
    CA2297176A1|1997-04-24|1998-10-29|Ortho-Mcneil Pharmaceutical, Inc.|Substituted imidazoles useful in the treatment of inflammatory diseases|
    WO1999001145A1|1997-07-03|1999-01-14|Osiris Therapeutics, Inc.|Human mesenchymal stem cells from peripheral blood|
    DK1015576T3|1997-09-16|2005-08-29|Egea Biosciences Llc|Method for complete chemical synthesis and aggregation of genes and genomes|
    US6670127B2|1997-09-16|2003-12-30|Egea Biosciences, Inc.|Method for assembly of a polynucleotide encoding a target polypeptide|
    EP1025204A4|1997-10-23|2001-02-28|Geron Corp|Methods and materials for the growth of primate-derived primordial stem cells|
    ZA9811898B|1997-12-29|2000-06-28|Ortho Mcneil Pharm Inc|Anti-Inflammatory Compounds.|
    AT316795T|1998-03-18|2006-02-15|Osiris Therapeutics Inc|MESENCHYMAL STEM CELLS FOR THE PREVENTION AND TREATMENT OF IMMUNE RESPONSES IN TRANSPLANTATIONS|
    MY132496A|1998-05-11|2007-10-31|Vertex Pharma|Inhibitors of p38|
    US6610540B1|1998-11-18|2003-08-26|California Institute Of Technology|Low oxygen culturing of central nervous system progenitor cells|
    US6413556B1|1999-01-08|2002-07-02|Sky High, Llc|Aqueous anti-apoptotic compositions|
    US6458593B1|1999-01-21|2002-10-01|Vitro Diagnostics, Inc.|Immortalized cell lines and methods of making the same|
    US6815203B1|1999-06-23|2004-11-09|Joslin Diabetes Center, Inc.|Methods of making pancreatic islet cells|
    US6306424B1|1999-06-30|2001-10-23|Ethicon, Inc.|Foam composite for the repair or regeneration of tissue|
    US6333029B1|1999-06-30|2001-12-25|Ethicon, Inc.|Porous tissue scaffoldings for the repair of regeneration of tissue|
    US6685936B2|1999-10-12|2004-02-03|Osiris Therapeutics, Inc.|Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation|
    US20030082155A1|1999-12-06|2003-05-01|Habener Joel F.|Stem cells of the islets of langerhans and their use in treating diabetes mellitus|
    WO2001042789A1|1999-12-13|2001-06-14|The Scripps Research Institute|MARKERS FOR IDENTIFICATION AND ISOLATION OF PANCREATIC ISLET α AND β CELL PROGENITORS|
    US7410798B2|2001-01-10|2008-08-12|Geron Corporation|Culture system for rapid expansion of human embryonic stem cells|
    US6667176B1|2000-01-11|2003-12-23|Geron Corporation|cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells|
    US7005252B1|2000-03-09|2006-02-28|Wisconsin Alumni Research Foundation|Serum free cultivation of primate embryonic stem cells|
    US7439064B2|2000-03-09|2008-10-21|Wicell Research Institute, Inc.|Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium|
    US6436704B1|2000-04-10|2002-08-20|Raven Biotechnologies, Inc.|Human pancreatic epithelial progenitor cells and methods of isolation and use thereof|
    US6458589B1|2000-04-27|2002-10-01|Geron Corporation|Hepatocyte lineage cells derived from pluripotent stem cells|
    CN1449439A|2000-06-26|2003-10-15|株式会社雷诺再生医学研究所|Cell fraction containing cells capable of differentiating into nervous system cells|
    CZ20031125A3|2000-10-23|2003-10-15|Smithkline Beecham Corporation|Novel compounds|
    CA2431187A1|2000-12-08|2002-06-13|Ortho-Mcneil Pharmaceutical, Inc.|Macroheterocylic compounds useful as kinase inhibitors|
    US6849643B2|2000-12-08|2005-02-01|Ortho-Mcneil Pharmaceutical, Inc.|Indazolyl-substituted pyrroline compounds as kinase inhibitors|
    US6599323B2|2000-12-21|2003-07-29|Ethicon, Inc.|Reinforced tissue implants and methods of manufacture and use|
    JP2005503759A|2001-01-24|2005-02-10|アメリカ合衆国|Differentiation of stem cells into pancreatic endocrine cells|
    WO2002059130A1|2001-01-25|2002-08-01|The United States Of America, Represented By The Secretary, Department Of Health And Human Services|Formulation of boronic acid compounds|
    US6656488B2|2001-04-11|2003-12-02|Ethicon Endo-Surgery, Inc.|Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering|
    JP2004527249A|2001-04-19|2004-09-09|デヴェロゲンアクチエンゲゼルシャフトフュアエントヴィックルングスビオローギッシェフォルシュング|Method of differentiating stem cells into insulin producing cells|
    EP1391505B1|2001-04-24|2009-01-28|Ajinomoto Co., Inc.|Stem cells and method of separating the same|
    CA2447015A1|2001-05-15|2002-11-21|Rappaport Family Institute For Research In The Medical Sciences|Insulin producing cells derived from human embryonic stem cells|
    US6626950B2|2001-06-28|2003-09-30|Ethicon, Inc.|Composite scaffold with post anchor for the repair and regeneration of tissue|
    KR100418195B1|2001-07-05|2004-02-11|주식회사 우리기술|Apparatus and method for multi-testing insulation of power cables|
    GB0117583D0|2001-07-19|2001-09-12|Astrazeneca Ab|Novel compounds|
    WO2003014313A2|2001-08-06|2003-02-20|Bresagen, Ltd.|Alternative compositions and methods for the culture of stem cells|
    US6617152B2|2001-09-04|2003-09-09|Corning Inc|Method for creating a cell growth surface on a polymeric substrate|
    JP2005506074A|2001-10-18|2005-03-03|イクシオン・バイオテクノロジー・インコーポレーテッド|Conversion of hepatic stem and progenitor cells into functional pancreatic cells|
    WO2003042405A2|2001-11-15|2003-05-22|Children's Medical Center Corporation|Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof|
    CN1630526B|2001-12-07|2010-05-05|马克罗珀尔生物外科公司|Systems and methods for treating patients with processed lipoaspirate cells|
    EP1463798A4|2001-12-07|2005-01-19|Geron Corp|Islet cells from human embryonic stem cells|
    WO2003054169A1|2001-12-21|2003-07-03|Thromb-X Nv|Compositions for the in vitro derivation and culture of embryonic stem cell lines with germline transmission capability|
    US20030162290A1|2002-01-25|2003-08-28|Kazutomo Inoue|Method for inducing differentiation of embryonic stem cells into functioning cells|
    WO2003087349A1|2002-04-17|2003-10-23|Otsuka Pharmaceutical Co., Ltd.|METHOD OF FORMING PANCREATIC β CELLS FROM MESENCHYMAL CELLS|
    US20040161419A1|2002-04-19|2004-08-19|Strom Stephen C.|Placental stem cells and uses thereof|
    JP2005529918A|2002-05-08|2005-10-06|ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ|Substituted pyrroline kinase inhibitors|
    US20090203141A1|2003-05-15|2009-08-13|Shi-Lung Lin|Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant RNA agents|
    US20060003446A1|2002-05-17|2006-01-05|Gordon Keller|Mesoderm and definitive endoderm cell populations|
    US20060122104A1|2002-05-28|2006-06-08|Presnell Sharon C|Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells|
    KR20050008787A|2002-06-05|2005-01-21|얀센 파마슈티카 엔.브이.|Bisindolyl-maleimid derivatives as kinase inhibitors|
    GB0212976D0|2002-06-06|2002-07-17|Tonejet Corp Pty Ltd|Ejection method and apparatus|
    CN1171991C|2002-07-08|2004-10-20|徐如祥|Culture process of human nerve stem cell|
    US6877147B2|2002-07-22|2005-04-05|Broadcom Corporation|Technique to assess timing delay by use of layout quality analyzer comparison|
    US7838290B2|2002-07-25|2010-11-23|The Scripps Research Institute|Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith|
    EP1539930A4|2002-07-29|2006-08-09|Es Cell Int Pte Ltd|Multi-step method for the differentiation of insulin positive, glucose|
    WO2004016747A2|2002-08-14|2004-02-26|University Of Florida|Bone marrow cell differentiation|
    EP1539928A4|2002-09-06|2006-09-06|Amcyte Inc|Cd56 positive human adult pancreatic endocrine progenitor cells|
    US9969977B2|2002-09-20|2018-05-15|Garnet Biotherapeutics|Cell populations which co-express CD49c and CD90|
    US20040062753A1|2002-09-27|2004-04-01|Alireza Rezania|Composite scaffolds seeded with mammalian cells|
    US20050260158A1|2003-11-07|2005-11-24|Eliezer Huberman|Human stem cell materials and methods|
    US20050003534A1|2002-11-07|2005-01-06|Eliezer Huberman|Human stem cell materials and methods|
    US20060252150A1|2002-11-08|2006-11-09|Linzhao Cheng|Human embryonic stem cell cultures, and compositions and methods for growing same|
    US7144999B2|2002-11-23|2006-12-05|Isis Pharmaceuticals, Inc.|Modulation of hypoxia-inducible factor 1 alpha expression|
    AU2003302702B2|2002-12-05|2008-08-07|Technion Research & Development Foundation Ltd.|Cultured human pancreatic islets, and uses thereof|
    ES2571355T3|2002-12-16|2016-05-24|Technion Res & Dev Foundation|Culture system without feeder cells or xenocontaminants for human embryonic stem cells|
    US20070155661A1|2003-02-14|2007-07-05|The Board Of Trustees Of The Leland Standord Junior University|Methods and compositions for modulating the development of stem cells|
    WO2005045001A2|2003-02-14|2005-05-19|The Board Of Trustees Of The Leland Stanford Junior University|Insulin-producing cells derived from stem cells|
    US20070020242A1|2003-03-27|2007-01-25|Ixion Biotechnology, Inc.|Method for transdifferentiation of non-pancreatic stem cells to the pancreatic pathway|
    US20060194315A1|2003-03-31|2006-08-31|Condie Brian G|Compositions and methods for the control, differentiaton and/or manipulation of pluripotent cells through a gamma-secretase signaling pathway|
    WO2005010524A1|2003-06-04|2005-02-03|Curis, Inc.|Stem cell-based methods for identifying and characterizing agents|
    ES2554343T3|2003-06-27|2015-12-18|DePuy Synthes Products, Inc.|Postpartum cells derived from umbilical cord tissue and methods of preparing and using them|
    IL161903D0|2003-07-17|2005-11-20|Gamida Cell Ltd|Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs|
    ITRM20030395A1|2003-08-12|2005-02-13|Istituto Naz Per Le Malattie Infettive Lazz|CULTURE GROUND FOR MAINTENANCE, PROLIFERATION AND DIFFERENTIATION OF MAMMALIAN CELLS.|
    WO2005017117A2|2003-08-14|2005-02-24|Martin Haas|Multipotent amniotic fetal stem cells and banking of same|
    US7157275B2|2003-08-15|2007-01-02|Becton, Dickinson And Company|Peptides for enhanced cell attachment and growth|
    US20060205072A1|2003-08-27|2006-09-14|Nobuko Uchida|Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations|
    CA2544252A1|2003-11-04|2005-05-26|U.S. Department Of Veterans Affairs|Stem cell culture medium and method of using said medium and the cells|
    CA2550010A1|2003-12-17|2005-06-30|Allergan, Inc.|Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b|
    US20060030042A1|2003-12-19|2006-02-09|Ali Brivanlou|Maintenance of embryonic stem cells by the GSK-3 inhibitor 6-bromoindirubin-3'-oxime|
    WO2005063971A2|2003-12-23|2005-07-14|Cythera, Inc|Definitive endoderm|
    US20050266554A1|2004-04-27|2005-12-01|D Amour Kevin A|PDX1 expressing endoderm|
    US7625753B2|2003-12-23|2009-12-01|Cythera, Inc.|Expansion of definitive endoderm cells|
    EA011953B1|2004-04-27|2009-06-30|Китера, Инк.|Pdx1 expressing endoderm|
    WO2006016999A1|2004-07-09|2006-02-16|Cythera, Inc.|Methods for identifying factors for differentiating definitive endoderm|
    US20050233446A1|2003-12-31|2005-10-20|Parsons Xuejun H|Defined media for stem cell culture|
    TWI334443B|2003-12-31|2010-12-11|Ind Tech Res Inst|Method of single cell culture of undifferentiated human embryonic stem cells|
    US20080241107A1|2004-01-23|2008-10-02|Copland Iii John A|Methods and Compositions For Preparing Pancreatic Insulin Secreting Cells|
    GB2441530B|2004-02-12|2009-09-23|Univ Newcastle|Stem Cells|
    AU2005221095A1|2004-03-09|2005-09-22|John J. O'neil|Methods for generating insulin-producing cells|
    JP2007528226A|2004-03-10|2007-10-11|リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア|Composition and method for propagation of embryonic stem cells|
    US7585672B2|2004-04-01|2009-09-08|Wisconsin Alumni Research Foundation|Differentiation of stem cells to endoderm and pancreatic lineage|
    EP1791952A4|2004-08-13|2008-06-11|Univ Georgia Res Found|Compositions and methods for self-renewal and differentiation in human embryonic stem cells|
    WO2006026473A2|2004-08-25|2006-03-09|University Of Georgia Research Foundation, Inc.|METHODS AND COMPOSITIONS UTILIZING MYC AND GSK3ß TO MANIPULATE THE PLURIPOTENCY OF EMBRYONIC STEM CELLS|
    DE102004043256B4|2004-09-07|2013-09-19|Rheinische Friedrich-Wilhelms-Universität Bonn|Scalable process for culturing undifferentiated stem cells in suspension|
    KR20070058584A|2004-09-08|2007-06-08|위스콘신 얼럼나이리서어치 화운데이션|Culturing human embryonic stem cells|
    BRPI0514778B1|2004-09-08|2018-07-10|Wisconsin Alumni Research Foundation|MEASURE TO GROW EMBRYONIC STEM CELLS|
    US7846467B2|2005-01-13|2010-12-07|Minas Theodore Coroneo|Ocular scaffold for stem cell cultivation and methods of use|
    WO2006083782A2|2005-01-31|2006-08-10|Es Cell International Pte Ltd.|Directed differentiation of embryonic stem cells and uses thereof|
    JP4988606B2|2005-02-28|2012-08-01|サンガモバイオサイエンシズインコーポレイテッド|Anti-angiogenic methods and compositions|
    PL1860950T3|2005-03-04|2017-09-29|Lifescan, Inc.|Adult pancreatic derived stromal cells|
    GB0505970D0|2005-03-23|2005-04-27|Univ Edinburgh|Culture medium containing kinase inhibitor, and uses thereof|
    US7998938B2|2005-04-15|2011-08-16|Geron Corporation|Cancer treatment by combined inhibition of proteasome and telomerase activities|
    US20080208351A1|2005-04-26|2008-08-28|Aarhus Universitet|Biocompatible Material for Surgical Implants and Cell Guiding Tissue Culture Surfaces|
    JP2008545442A|2005-06-10|2008-12-18|アイアールエム・リミテッド・ライアビリティ・カンパニー|Compounds that maintain the pluripotency of embryonic stem cells|
    WO2006138433A2|2005-06-14|2006-12-28|The Regents Of The University Of California|Induction of cell differentiation by class i bhlh polypeptides|
    EP1931764A1|2005-06-21|2008-06-18|GE Healthcare Bio-Sciences AB|Method for cell culture|
    CN101341138B|2005-06-30|2012-11-14|詹森药业有限公司|Cyclic anilino-pyridinotriazines as GSK-3 inhibitors|
    US20080194021A1|2005-07-29|2008-08-14|Mays Robert W|Use of a Gsk-3 Inhibitor to Maintain Potency of Culture Cells|
    WO2007012144A1|2005-07-29|2007-02-01|Australian Stem Cell Centre Limited|Compositions and methods for growth of pluripotent cells|
    BRPI0617085A2|2005-09-02|2016-11-08|Agency Science Tech & Res|method for obtaining a mesenchymal stem cell , cell or cell line, method for deriving a cell culture from an embryonic stem cell, method for treating a disease, use of a mesenchymal stem cell, differentiated lineage, pharmaceutical composition, method for conditioning a cell culture medium, conditioned medium and use thereof, method for obtaining a polypeptide, method for obtaining a cell culture, cell culture, mesenchymal stem cell, mesenchymal stem cell line or a differentiated mesenchymal cell|
    GB2444686B|2005-09-12|2010-08-25|Es Cell Int Pte Ltd|Differentiation of pluripotent stem cells using p38 MAPK inhibitors or prostaglandins|
    SG169324A1|2005-10-14|2011-03-30|Univ Minnesota|Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype|
    EP2674485B1|2005-10-27|2019-06-12|Viacyte, Inc.|Pdx-1 expressing dorsal and ventral foregut endoderm|
    WO2007082963A1|2006-01-18|2007-07-26|Fundación Instituto Valenciano De Infertilidad|Human embryo stem-cell lines and methods for using same|
    US8153429B2|2006-02-23|2012-04-10|Viacyte, Inc.|Compositions and methods useful for culturing differentiable cells|
    US7695965B2|2006-03-02|2010-04-13|Cythera, Inc.|Methods of producing pancreatic hormones|
    AU2007277364B2|2006-07-26|2010-08-12|Viacyte, Inc.|Methods of producing pancreatic hormones|
    DK2650360T3|2006-03-02|2019-10-07|Viacyte Inc|Endocrine precursor cells, pancreatic hormone-expressing cells, and methods of preparation|
    US8741643B2|2006-04-28|2014-06-03|Lifescan, Inc.|Differentiation of pluripotent stem cells to definitive endoderm lineage|
    EP3527658A1|2006-04-28|2019-08-21|Lifescan, Inc.|Differentiation of human embryonic stem cells|
    JP5288209B6|2006-05-02|2018-06-27|ウイスコンシン アラムニ リサーチ ファンデーション|Methods for differentiating stem cells into endoderm cells and pancreatic lineage cells|
    US7964402B2|2006-05-25|2011-06-21|Sanford-Burnham Medical Research Institute|Methods for culture and production of single cell populations of human embryonic stem cells|
    US8415153B2|2006-06-19|2013-04-09|Geron Corporation|Differentiation and enrichment of islet-like cells from human pluripotent stem cells|
    CN100494359C|2006-06-23|2009-06-03|中日友好医院|Method for in vitro amplifying and in 3D solid culturing for nerve stem cell|
    US20080003676A1|2006-06-26|2008-01-03|Millipore Corporation|Growth of embryonic stem cells|
    PL2046946T3|2006-06-26|2017-04-28|Lifescan, Inc.|Pluripotent stem cell culture|
    GB2454386B|2006-07-06|2011-07-06|Es Cell Int Pte Ltd|Method for embryonic stem cell culture on a positively charged support surface|
    KR101331510B1|2006-08-30|2013-11-20|재단법인서울대학교산학협력재단|Media compostions containing low concentrations of glucose useful for human embryonic stem cells, differentiation method of human embryonic stem cells into insulin-producing cells or cell clusters using thereof, and insulin-producing cells or cell clusters differentiated thereby|
    JP2008099662A|2006-09-22|2008-05-01|Institute Of Physical & Chemical Research|Method for culturing stem cell|
    US20080091234A1|2006-09-26|2008-04-17|Kladakis Stephanie M|Method for modifying a medical implant surface for promoting tissue growth|
    US20100323442A1|2006-10-17|2010-12-23|Emmanuel Edward Baetge|Modulation of the phosphatidylinositol-3-kinase pathway in the differentiation of human embryonic stem cells|
    US8835163B2|2006-10-18|2014-09-16|The Board Of Trustees Of The University Of Illinois|Embryonic-like stem cells derived from adult human peripheral blood and methods of use|
    TW200836749A|2007-01-09|2008-09-16|Vioquest Pharmaceuticals Inc|Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof|
    CA2676044C|2007-01-30|2019-10-22|University Of Georgia Research Foundation, Inc.|Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells |
    GB0703188D0|2007-02-19|2007-03-28|Roger Land Building|Large scale production of stem cells|
    BRPI0814425A2|2007-07-18|2014-10-21|Lifescan Inc|DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS|
    CA3114827A1|2007-07-31|2009-02-05|Lifescan, Inc.|Differentiation of human embryonic stem cells to pancreatic endocrine|
    KR101544498B1|2007-08-24|2015-08-17|스티칭 허트 네덜란드 칸커 인스티튜트|Compositions for the treatment of neoplastic diseases|
    CA2706560C|2007-11-27|2017-02-28|Lifescan, Inc.|Differentiation of human embryonic stem cells to pancreatic cells|
    SG154367A1|2008-01-31|2009-08-28|Es Cell Int Pte Ltd|Method of differentiating stem cells|
    EP2250252A2|2008-02-11|2010-11-17|Cambridge Enterprise Limited|Improved reprogramming of mammalian cells, and the cells obtained|
    WO2009105570A2|2008-02-21|2009-08-27|Centocor Ortho Biotech Inc.|Methods, surface modified plates and compositions for cell attachment, cultivation and detachment|
    WO2009116951A2|2008-03-17|2009-09-24|Agency For Science, Technology And Research|Microcarriers for stem cell culture|
    EP2727998B1|2008-04-21|2019-06-12|Viacyte, Inc.|Methods for purifying pancreatic endoderm cells derived from human embryonic stem cells|
    US20090298178A1|2008-06-03|2009-12-03|D Amour Kevin Allen|Growth factors for production of definitive endoderm|
    DE102008032236A1|2008-06-30|2010-04-01|Eberhard-Karls-Universität Tübingen|Isolation and / or identification of stem cells with adipocytic, chondrocytic and pancreatic differentiation potential|
    KR101734501B1|2008-06-30|2017-05-11|얀센 바이오테크 인코포레이티드|Differentiation of pluripotent stem cells|
    US20100028307A1|2008-07-31|2010-02-04|O'neil John J|Pluripotent stem cell differentiation|
    AU2009308967C1|2008-10-31|2017-04-20|Janssen Biotech, Inc.|Differentiation of human embryonic stem cells to the pancreatic endocrine lineage|
    US8008075B2|2008-11-04|2011-08-30|Viacyte, Inc.|Stem cell aggregate suspension compositions and methods of differentiation thereof|
    GB2485113B|2009-07-20|2016-12-28|Janssen Biotech Inc|Differentiation of human embryonic stem cells into cells of the pancreatic endoderm lineage|
    EP2542666A4|2010-03-02|2014-05-07|Univ Singapore|Culture additives to boost stem cell proliferation and differentiation response|EP3025713A1|2005-02-09|2016-06-01|Santen Pharmaceutical Co., Ltd|Liquid formulations for treatment of diseases or conditions|
    US8663639B2|2005-02-09|2014-03-04|Santen Pharmaceutical Co., Ltd.|Formulations for treating ocular diseases and conditions|
    US7959949B2|2006-04-27|2011-06-14|University Of Central Florida Research Foundation, Inc.|Functionalized nanoceria composition for ophthalmic treatment|
    US8916199B1|2008-04-25|2014-12-23|University of Central Florida Research Foundation, Ind.|Inhibition of angiogenesis associated with ovarian cancer by nanoparticles of cerium oxide|
    EP2001438A2|2006-02-09|2008-12-17|Macusight, Inc.|Stable formulations, and methods of their preparation and use|
    AU2007230964B2|2006-03-23|2012-07-19|Santen Pharmaceutical Co., Ltd.|Formulations and methods for vascular permeability-related diseases or conditions|
    WO2007127408A2|2006-04-28|2007-11-08|Tulane University Health Sciences Center|Methods for treating diabetes|
    US20070292401A1|2006-06-20|2007-12-20|Harmon Alexander M|Soft tissue repair and regeneration using stem cell products|
    JP6041456B2|2006-07-12|2016-12-07|メゾブラスト，インコーポレーテッド|Treatment of excessive neovascularization|
    US9119391B1|2007-07-16|2015-09-01|University Of Central Florida Research Foundation, Inc.|Polymer coated ceria nanoparticles for selective cytoprotection|
    WO2008083401A1|2007-01-02|2008-07-10|University Of Central Florida Research Foundation Inc.|Methods and materials for stimulating proliferation of stem cells|
    US8318485B2|2008-02-25|2012-11-27|Natalie Gavrilova|Stem cell therapy for the treatment of diabetic retinopathy and diabetic optic neuropathy|
    US20090220995A1|2008-02-28|2009-09-03|Sachs David H|Multiple administrations of umbilicus derived cells|
    US9458431B2|2008-03-17|2016-10-04|Agency For Science, Technology And Research|Microcarriers for stem cell culture|
    WO2009116951A2|2008-03-17|2009-09-24|Agency For Science, Technology And Research|Microcarriers for stem cell culture|
    US8828720B2|2008-03-17|2014-09-09|Agency For Science, Technology And Research|Microcarriers for stem cell culture|
    US20110143433A1|2008-03-17|2011-06-16|Agency For Science, Technology And Research|Microcarriers for Stem Cell Culture|
    CA2723480A1|2008-04-25|2009-10-29|The Board Of Regents Of The University Of Oklahoma|Inhibition of neovascularization by cerium oxide nanoparticles|
    US9127202B1|2008-07-18|2015-09-08|University Of Central Florida Research Foundation, Inc.|Biocompatible nano rare earth oxide upconverters for imaging and therapeutics|
    CN102202680A|2008-09-04|2011-09-28|Abt控股公司|Use of stem cells to prevent neuronal dieback|
    US8883519B1|2009-03-17|2014-11-11|University Of Central Florida Research Foundation, Inc.|Oxidase activity of polymeric coated cerium oxide nanoparticles|
    EP2251028A1|2009-05-12|2010-11-17|Biocompatibles Uk Ltd.|Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor|
    US9585840B1|2009-07-10|2017-03-07|University Of Central Florida Research Foundation, Inc.|Redox active cerium oxide nanoparticles and associated methods|
    US8795731B1|2009-10-12|2014-08-05|University Of Central Florida Research Foundation, Inc.|Cerium oxide nanoparticle-based device for the detection of reactive oxygen species and monitoring of chronic inflammation|
    CN102048756B|2009-11-04|2014-02-19|中国医学科学院基础医学研究所|Use of human fat-derived mesenchymal stem cells in treatment of diseases in kidney and ocular fundus|
    WO2012036786A1|2010-09-17|2012-03-22|University Of L'aquila|Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of alzheimer's disease|
    RU2467730C2|2011-01-19|2012-11-27|Александр Дмитриевич Ромащенко|Method for integrated pathogenetic treatment of central and peripheral tapetoretinal dystrophies with applying cell technologies|
    RU2467727C2|2011-02-11|2012-11-27|Александр Дмитриевич Ромащенко|Method of treating wet age-related macular degeneration of retina with using cell transplantation|
    US8951539B1|2011-06-07|2015-02-10|University Of Central Florida Research Foundation, Inc.|Methods of promoting angiogenesis using cerium oxide nanoparticles|
    EP2554662A1|2011-08-05|2013-02-06|M Maria Pia Cosma|Methods of treatment of retinal degeneration diseases|
    US9161950B2|2011-09-21|2015-10-20|University Of Central Florida Foundation, Inc.|Neuronal protection by cerium oxide nanoparticles|
    US9463437B2|2013-02-14|2016-10-11|University Of Central Florida Research Foundation, Inc.|Methods for scavenging nitric oxide using cerium oxide nanoparticles|
    US9274071B2|2013-12-30|2016-03-01|General Electric Company|Methods for assessing cell culture fluid by impedance spectra|
    US10736934B2|2015-11-13|2020-08-11|The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Proteasome modulation for treatment of corneal disorders|
    EP3332695B1|2016-12-09|2021-05-26|Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.|Measurement device|
    JP2022516187A|2019-01-03|2022-02-24|メゾブラスト・インターナショナル・エスアーエールエル|How to improve your eyesight|
    法律状态:
    2012-05-31| FGA| Letters patent sealed or granted (standard patent)|
    2021-01-07| MK14| Patent ceased section 143(a) (annual fees not paid) or expired|
    优先权:
    申请号 | 申请日 | 专利标题
    US68863705P| true| 2005-06-08|2005-06-08||
    US60/688,637||2005-06-08||
    PCT/US2006/021671|WO2006133052A2|2005-06-08|2006-06-02|A cellular therapy for ocular degeneration|
    [返回顶部]